Current Targets for Anticancer Drug Discovery

N-H. Nam; K. Parang
February 2003
Current Drug Targets;Feb2003, Vol. 4 Issue 2, p159
Academic Journal
The call for the discovery of less toxic, more selective, and more effective agents to treat cancer has become more urgent. Inhibition of angiogenesis continues to be one of the main streams in the current cancer drug discovery activity. Insights into tumor angiogenesis biology have led to the identification of a number of molecules, which are important for the progression of these processes. Of particular interest is a group of growth factors including fibroblast growth factor, platelet-derived growth factor, and vascular endothelial growth factor. These growth factors and their corresponding receptor tyrosine kinases have become important targets for inhibition of the proliferation of endothelial cells, the main component of blood vessels. The validated targets for inhibition of angiogenesis also include a family of matrix metalloproteinases and cell adhesion molecules. In the closely related area, protein kinases have emerged as one of the most important targets for drug discovery. Besides growth factor receptor tyrosine kinases, numerous other protein kinases implicated in malignancies have been identified including non-receptor kinases such as Bcl-Abl and Src kinases. In addition, the cell cycle regulators (cyclin-dependent kinases, p21 gene) and apoptosis modulators (Bcl-2 oncoprotein, p53 tumor suppressor gene, survivin protein, etc) have also attracted renewed interest as potential targets for anticancer drug discovery. Other molecular targets include protein farnesyltransferase (FTase), histone deacetylase (HDAC), and telomerase, which have essential roles in cellular signal transduction pathways (FTase, HDAC) and cell life-span (telomerase). This review presents a comprehensive summary and discussion on the most important targets currently attracting a great deal of interest in contemporary anticancer drug design and discovery. Recent advances complementing these targets are also highlighted.


Related Articles

  • The history of angiogenesis inhibitors. Ribatti, D. // Leukemia (08876924);Aug2007, Vol. 21 Issue 8, p1606 

    The author reflects on the results several clinical studies which reveal the history of angiogenesis inhibitors. He mentions the clinical finding which considers cartilage as a potential source of angiogenesis inhibitor because of its vascularity. Based on clinical observations, he suggests that...

  • Fresh from the pipeline: Gefitinib. Muhsin, Mohamed; Graham, Joanne; Kirkpatrick, Peter // Nature Reviews Drug Discovery;Jul2003, Vol. 2 Issue 7, p515 

    Gefitinib (Iressa; AstraZeneca) is the first in a new class of targeted anticancer drugs that inhibit the tyrosine kinase activity of the epidermal growth factor receptor. Following Japanese approval in 2002, gefitinib was approved by the US FDA in May 2003 for the treatment of advanced...

  • In this issue.  // Nature Reviews Drug Discovery;Nov2010, Vol. 9 Issue 11, p821 

    The article discusses various reports published within the issue, including one by Brinkmann and colleagues on the case history of fingolimod, one by Cohen on cyclical development strategy, and one by Doroshow and colleagues on their evaluation of anticancer agents at the U.S. National Cancer...

  • Anticancer chemotherapy. Davey, Peter; Tudhope, G.R. // British Medical Journal (Clinical Research Edition);7/9/1983, Vol. 287 Issue 6385, p107 

    Features several of the latest cytotoxic drugs and its applications in Great Britain. Current drugs and their analogues; Developments with antimetabolites; Enumerations on latest cytotoxic drugs.

  • Dynamic Contrast-Enhanced MRI in Oncology Drug Development. Cheng, Hai-Ling Margaret // Current Clinical Pharmacology;May2007, Vol. 2 Issue 2, p111 

    Angiogenesis, long recognized as a key factor in tumor growth and metastasis, has been the target of new anticancer treatment paradigms. Development of antiangiogenesis drugs is challenging, mainly due to the difficulty of determining the correct dosage and the time required to observe a...

  • Drug Discovery in Ovarian Cancer. Chase, Dana M.; Mathur, Nidhee; Tewari, Krishnansu S. // Recent Patents on Anti-Cancer Drug Discovery;Nov2010, Vol. 5 Issue 3, p251 

    Drug discovery in the ovarian cancer arena has led to the activation of several important clinical trials. Many biologic agents have come down the pipeline and are being studied in phase II trials for recurrent disease. These agents include antivascular compounds that disrupt angiogenesis...

  • Challenges of Cancer Drug Design A Drug Metabolism Perspective. Sanchez, R.I.; Mesia-Vela, S.; Kauffman, F.C. // Current Cancer Drug Targets;May2001, Vol. 1 Issue 1, p1 

    The time course and duration of action of drugs used in cancer chemotherapy are greatly influenced by the molecular and biochemical properties of enzymes associated with their metabolism. Variation in the response of individual patients to cancer chemotherapeutic agents is in large measure due...

  • Potential Application of Peptides in Tumor Targeting and Anticancer Therapeutics. Prakash, Jai // Current Pharmaceutical Biotechnology;Aug2011, Vol. 12 Issue 8, p1087 

    No abstract available.

  • Opinion: ImClone/UCB: tapping into a rich vein.  // PharmaWatch: Cancer;Oct2005, Vol. 4 Issue 10, p11 

    Focuses on a partnership between ImClone Systems Inc. and UCB Group Ltd. to co-develop an early-stage cancer drug. Terms of the alliance; Renewal of interest in angiogenesis inhibitors; Process of drug approval.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics